ADIPOQ and Insulin resistance: Jandeleit-Dahm et al. [19] found that, in obese, insulin-resistant, or hypertensive subjects, treatment with Ang II AT1 receptor antagonists reduces insulin resistance and reduces new cases of DM2, suggesting a relationship between Ang II, leptin, and adiponectin.